American Association for Cancer Research Virtual Annual Meeting II
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with newly diagnosed, MGMT-unmethylated glioblastoma
American Association for Cancer Research Virtual Annual Meeting II
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting
American Association for Cancer Research Virtual Annual Meeting II
Dianhydrogalactitol (VAL-083) synergizes with topoisomerase inhibitors to overcome homologous recombination repair activity in glioblastoma and prostate cancer cells
American Association for Cancer Research Virtual Annual Meeting II
Dianhydrogalactitol (VAL-083) exhibits strong efficacy in GBM tumors with different epigenetic background and treatment history
Luxembourg Institute of Health
Efficacy of VAL-083 in primary and recurrent brain tumor biopsies. VAL-083 showed consistent and superior anti-tumor activity against MGMT-unmethylated tumors in comparison to temozolomide
Society for Neuro-Oncology Annual Meeting 2019
Key Opinion Leader Event Audio
Society for Neuro-Oncology Annual Meeting 2019
Key Opinion Leader Event Transcript
Society for Neuro-Oncology Annual Meeting 2019
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting
Society for Neuro-Oncology Annual Meeting 2019
Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM: Half-Way Report
AACR Annual Meeting 2019
Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo